New Clinical Trial Led by Mass General Brigham Reveals Solriamfetol Effectively Combats Severe Fatigue in Early Morning Shift Workers

The modern global economy relies heavily on a workforce operating far outside the traditional nine-to-five window. While much public discourse and medical research have historically centered on the well-documented perils of overnight shift schedules, a significantly larger population of employees quietly contends with the grueling demands of very early morning shifts. Millions of people routinely begin their professional duties before dawn, fighting a severe biological imperative to sleep. A groundbreaking clinical trial recently spearheaded by researchers at Mass General Brigham has demonstrated that the wake-promoting pharmaceutical agent solriamfetol, commercially known as Sunosi, can substantially enhance alertness and cognitive functioning in early morning shift workers suffering from shift work disorder.
Published in the prestigious medical journal NEJM Evidence, the study marks a critical milestone in sleep medicine. For decades, the medical community has recognized shift work disorder as a debilitating condition characterized by severe, chronic insomnia or excessive daytime sleepiness directly linked to a misalignment between an individual’s work schedule and their internal circadian rhythm. However, therapeutic interventions have historically bypassed the demographic grappling with pre-dawn start times. This new investigation provides the first robust clinical evidence that targeted pharmacological intervention can successfully mitigate the profound physiological toll exacted by early morning labor, offering a potential lifeline to countless healthcare providers, transportation workers, emergency responders, and service industry employees.
Understanding the Hidden Biological Crisis of Pre-Dawn Schedules
To fully grasp the significance of the Mass General Brigham trial, one must examine the complex interplay between human biology and modern labor practices. Epidemiological data indicates that approximately one in four workers in industrialized nations operates outside standard daytime hours. Within this broad category, early morning schedules—typically requiring individuals to report for duty anywhere between 3:00 a.m. and 7:00 a.m.—represent the most prevalent form of shift work.
Despite the statistical dominance of these schedules, a distinct cultural perception persists. Many individuals who wake up in the dead of night to begin their jobs do not self-identify as traditional "shift workers." Instead, they view their routines merely as an early start to a normal day. Consequently, the chronic exhaustion they experience is frequently minimized, misattributed to poor sleep hygiene, or masked by high volumes of caffeine, rather than recognized as a diagnosable and treatable medical condition.
The root of the problem lies deep within the human brain. Dr. Charles A. Czeisler, chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, as well as the senior author of the study, emphasized the profound biological mismatch at play. The human body is governed by an internal master clock located in the suprachiasmatic nucleus of the hypothalamus. This circadian pacemaker regulates core body temperature, hormone secretion, and alertness cycles, anchoring wakefulness to daylight and sleep to darkness.
When an individual attempts to perform complex cognitive or physical tasks between 3:00 a.m. and 7:00 a.m., they are operating precisely at the circadian nadir—the biological window during which the brain is chemically programmed to prioritize deep sleep. Dr. Kirsi-Marja Zitting, an investigator within the same division and the study’s first author, noted that these workers face an extraordinary physiological hurdle. They are forced to remain highly focused and vigilant at a time when their neurological systems are signaling profound rest, creating what researchers describe as a double burden of acute sleep deprivation coupled with disrupted recovery sleep during daylight hours.
Health, Safety, and Economic Implications of Shift Work Disorder
The consequences of untreated shift work disorder extend far beyond mere daytime grogginess, presenting severe public health, workplace safety, and economic challenges. Chronic circadian misalignment has been systematically linked by numerous medical studies to a heightened risk of cardiovascular disease, metabolic syndrome, gastrointestinal disorders, type 2 diabetes, and certain forms of cancer.
From an immediate operational perspective, the cognitive deficits induced by shift work disorder degrade executive function, working memory, and reaction times. These impairments translate directly into elevated error rates across critical industries. In healthcare settings, fatigued nurses and physicians face a higher probability of medical errors. In the transportation and logistics sectors, drowsy operators contribute to catastrophic motor vehicle collisions and transit accidents. Furthermore, industrial settings see a spike in workplace injuries among sleep-deprived personnel.
Economically, the fallout manifests as billions of dollars in lost productivity, increased absenteeism, and elevated healthcare utilization. While wake-promoting agents such as modafinil have historically been prescribed to combat excessive sleepiness, their clinical profile presents notable limitations. Primarily studied and utilized among traditional overnight workers, these medications often possess long half-lives that can inadvertently disrupt subsequent restorative sleep phases, compounding the cycle of exhaustion.
Solriamfetol entered the clinical investigation as a uniquely promising candidate. Previously granted regulatory approval for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy, solriamfetol acts as a dopamine and norepinephrine reuptake inhibitor. Its pharmacological mechanism allows it to sustain wakefulness and mental acuity over extended durations without exerting a lingering disruptive effect on a patient’s primary sleep period later in the day.
Chronology and Design of the Clinical Trial
The journey toward validating solriamfetol for early morning shift workers involved a rigorously controlled clinical trial design executed by the multidisciplinary team at Mass General Brigham. The study enrolled 78 participants who met strict diagnostic criteria for shift work disorder while maintaining early morning employment schedules.
The investigative chronology unfolded across a multi-week evaluation framework:
- Screening and Baseline Assessment: Prospective participants underwent comprehensive medical and psychological evaluations to confirm a diagnosis of shift work disorder directly tied to their early morning occupational hours. Baseline cognitive performance and sleep architecture were documented.
- Randomization Phase: The 78 qualifying individuals were randomly assigned in a double-blind fashion to receive either active solriamfetol or an inactive placebo. Treatments were administered consistently on workdays over a rigorous four-week trial period.
- Controlled Simulation and Monitoring: Researchers assessed participants’ sustained attention and physiological ability to remain awake utilizing controlled, low-stimulation environments specifically calibrated to mirror the timing of their typical occupational shifts.
- Clinical Evaluation and Reporting: Throughout the four-week intervention, participants maintained detailed daily logs regarding their functional capacity, subjective alertness, and any potential adverse effects. They also engaged in regular clinical check-ins with the research staff.
Upon the conclusion of the four-week trial period, the data revealed a stark divergence between the cohort receiving solriamfetol and those administered the placebo. Participants taking solriamfetol exhibited statistically significant improvements in objective wakefulness metrics. They demonstrated a markedly reduced propensity for lapses in attention and were capable of maintaining stable alertness throughout the simulated duration of an entire eight-hour shift.
Evaluation of Results and Expert Analysis
The qualitative and quantitative feedback gathered during the trial underscored the practical, real-world utility of the treatment. Not only did the objective testing confirm enhanced neurological stability, but both the patients themselves and their attending clinicians reported tangible enhancements in overall daily functioning, occupational productivity, and the general quality of life.
Dr. Czeisler underscored the clinical significance of these outcomes, noting that the observed benefits extended far beyond statistical metrics. By enabling early morning workers to maintain cognitive engagement across an entire shift, the intervention addresses a fundamental vulnerability in modern labor structures. Essential workers across healthcare, public safety, and infrastructure sustain the daily operations of society, yet they frequently absorb an invisible biological tax in exchange for their labor. The findings suggest that modern medicine possesses the tools to alleviate this burden safely and effectively.
Despite the overwhelmingly positive trajectory of the trial, the research team maintains a measured, scientifically rigorous approach regarding the interpretation of their data. They emphasize that the current study was limited to a four-week duration and focused exclusively on otherwise healthy adult workers. Consequently, additional longitudinal research is required to evaluate the long-term safety profile, efficacy stability, and potential cumulative physiological impacts of sustained solriamfetol administration over extended periods.
Building upon the momentum of these findings, the investigative team at Mass General Brigham is actively pushing the boundaries of sleep medicine. Recruitment is currently underway for a subsequent clinical trial designed to evaluate the therapeutic efficacy of solriamfetol specifically within overnight shift worker populations. This ongoing research endeavor aims to broaden the clinical understanding of circadian rhythm disorders and potentially support expanded regulatory indications for solriamfetol as a comprehensive treatment for shift work disorder across all scheduling variations.
The study was supported by financial grants and research contributions from Jazz Pharmaceuticals, Axsome Therapeutics, and the Brigham and Women’s Hospital Center for Clinical Investigation, registered under clinical trial identifier NCT04788953. Alongside lead figures Dr. Czeisler and Dr. Zitting, the research collaborative included Mass General Brigham co-authors Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, and Jeanne F. Duffy, alongside independent researcher Eileen B. Leary. As research progresses, these findings offer a vital blueprint for safeguarding the health, performance, and well-being of the millions of essential workers who step into the dark to keep society moving forward.







